Selection. Selection, whereby one lineage is favoured over another and produces more surviving offspring, is a key force in evolution, as it leads to adaptation. In general, positive selection, the evolutionary force that increases the frequency of a lineage in a population, drives tumour progression 12 . Negative selection, also known as purifying selection, the evolutionary force by which cells with decreased fitness are eliminated from a population, also influences tumour evolution, for example, by removing potent neo-antigens 13,14 . However, selection is not Abstract | To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the genetic landscape of most cancer types, and cancer genomics approaches are driving new insights into cancer evolutionary patterns in time and space. In contrast to species evolution, cancer is a particular case owing to the vast size of tumour cell populations, chromosomal instability and its potential for phenotypic plasticity. Nevertheless, an evolutionary framework is a powerful aid to understand cancer progression and therapy failure. Indeed, such a framework could be applied to predict individual tumour behaviour and support treatment strategies.
This article is dedicated to the memory of Martin Gore.
Tumours are composed of subpopulations of cells (subclones) that can be distinguished on the basis of a variety of features that affect their phenotype, including genetic alterations such as single-nucleotide variants (SNVs), small insertions or deletions (indels), somatic copy number alterations (CNAs) and structural variants. Genetic intratumour heterogeneity has been documented across most cancers (reviewed elsewhere 1 ) and acts as a substrate for clonal evolution. The fundamental biological mechanisms underlying clonal evolution in cancer are similar to those that underpin the evolution of asexually reproducing species: replication, heritable variation, genetic drift, selection and environmental changes. Central to the neo-Darwinian synthesis of evolutionary biology is the paradigm of molecular evolution, that is, evolutionary change at the level of the DNA sequence, which links Mendelian genetics to Darwinian adaptation. Molecular evolution is relevant to cancer because the use of genomic sequencing is a key technology to understand temporal and spatial patterns of somatic evolution, the accumulation of genomic alterations in somatic cells. At the core of molecular evolution, in turn, is theoretical population genetics, which has been the fundamental mathematical formalism used to describe evolution for the past 90 years 2,3 . The same theoretical framework has been used to understand clonal evolution in cancer [4] [5] [6] [7] [8] [9] [10] [11] . The study of the evolutionary dynamics of cancer clones is fundamentally concerned with the relative frequencies of cancer subpopulations over space and time. Although some peculiarities of cancer evolution distinguish it from classic species evolution (Box 1), classical evolutionary theory can nevertheless be readily applied to understand cancer development.
Over the past 5 years, a number of next-generation sequencing studies have captured a variety of evolutionary patterns that shape cancer, showing their clinical relevance. Here, we provide an overview of the theoretical models of tumour evolution and the caveats around correctly interpreting genomic data and inferring evolutionary dynamics. We discuss the relevance of chromosome instability (CIN) as a driver of cancer evolution and, in particular, metastases; the clinical value of the evolutionary classification of cancer; and finally, the role of clonal evolution in treatment failure.
Current models of tumour evolution Cancer as a system is characterized by an astonishing com plexity and emergent behaviour. Nevertheless, this com plexity arises from the fairly simple, underlying evolutionary processes of mutation, genetic drift and selection, involving a large number of interacting agents (for example, the billions of cancer cells within a single lesion and the surrounding tumour microenvironment). The emergent behaviour gives rise to different observed 'modes' of evolution ( Fig. 1 ), which result from different combinations of the aforementioned fundamental processes in distinct contexts. In other words, because selective pressures change over time, so can the modes of evolution. Here, we discuss the principles of selection and different modes of evolution. operative at all times. Whereas mutation and drift occur continuously, and their rates depend on cell division and population dynamics, selection is dependent on the environmental context. For example, if there is no differential survival within a population, the lack of positive selection would mean that the population evolves neutrally (only mutation and drift are at play). Consequently, branching of a tumour phylogenetic tree does not always imply clonal selection, as branching is the natural product of mutational processes 15, 16 . Selection has the effect of pruning the tumour tree, for example, by favouring the expansion of some lineages (that is, branches) over others. The mutation rate itself could also be subject to selection. A higher mutation rate allows for diversification but also carries the risk of increasing the rate at which deleterious mutations, which perturb cancer growth, are acquired 17, 18 . For example, excessive CIN can result in cell-autonomous lethality; however, a just-right threshold of CIN may be evolutionarily advantageous. For example, mutations in the subunits of the anaphasepromoting complex (APC/C; also known as the cyc losome) may be selected during the evolution of chromo somally unstable tumour cell populations, resulting in lengthening of mitosis, suppression of chromosome missegregation and attenuation of excessive CIN 19 .
Mathematical models suggest that, in a growing population, mutator phenotypes are selected, because the cells that stochastically acquire positively selected mutations in effect doubly benefit from their own increased fitness and the negative fitness effect of deleterious mutations on the rest of the population 20 . Relatedly, modelling also suggests that a mutator phenotype increases the efficiency of carcinogenesis by making it more likely that a necessary set of mutations is acquired for transformation and cancer progression 18 .
Branching evolution. Evolution is always branched, because cell division and mutation continuously produce divergence at the level of genotypes. This fact is particularly true for cancer genomes, as cancers often have a mutator phenotype 21 . Hence, in principle, at any given time point, a tumour cell population consists of different cell lineages. Random fluctuations in the birth and death rates of these distinct lineages can lead to genetic drift, whereby one lineage produces more surviving offspring than another lineage and expands by chance. Genetic drift is referred to as a form of neutral evolution, as all lineages are neutral with respect to their chance of producing surviving offspring 22, 23 . Similar patterns of branching are also apparent in healthy tissue 24, 25 , emphasizing that branching is a necessary by-product of proliferating tissues. However, assuming no other limitations to growth, when a cancer subclone has increased fitness, it will expand owing to selection, as evidenced by the finding of subclonal cancer driver mutations and their impact on cancer progression 26, 27 . Selection is also evident in the finding of parallel evolution within the same tumour, in which distinct lineages acquire mutations in the same cancer driver gene, leading to parallel subclonal expansions (presented elsewhere 26, [28] [29] [30] ).
Linear evolution. The linear evolution model posits that only one lineage survives over time. However, as with the fossil record, it does not imply that there was only ever a single lineage that evolved in a stepwise fashion. If only a single clone survives to the point of sampling and then is detected, evolution will, of course, appear linear. However, conclusions regarding linear evolution from cancer genomic data are likely confounded by the limited sampling applied to the cancer in question and the limits of resolution by next-generation sequencing technologies.
Neutral evolution. Neutral evolution occurs in the absence of differential selection within a population and can be regarded as the evolution that occurs between selection events 31 . Before adaptive mutation occurs, the population evolves neutrally, and when the mutation arises, it initiates a clonal sweep that can be complete or incomplete. If the sweep is complete, and all the cells in the population carry the adaptive mutation, then the dynamics revert to neutral. Punctuated evolution. Punctuated evolution posits rapid bursts of adaptive evolution rather than continual gradual steps. If the adaptive mutation is a largescale alteration of the genome (for example, loss, gain, translocation or fusion of a chromosome), the adaptive clone has been referred to as a 'hopeful monster' 32, 33 . Compared with a small-scale mutation, an adapted clone genome is significantly altered, with the 'hopeful' referring to the likelihood that the mutation is adaptive. Punctuated equilibrium is a model that was first proposed by Eldredge and Gould in the early 1970s for species evolution 34 whereby adaptation occurs in a small spatially isolated niche until the newly adapted individuals rapidly expand out of the niche and through the wider population. Because the niche is small, the gradually adapting population is unlikely to be sampled before it expands, and therefore the evolutionary dynamics of the population at large are punctuated by the expansion of the adapted clone. Equilibrium refers to long periods of apparent clonal stasis during which the adapted clone persists at low, likely undetectable, frequency in the population.
Box 1 | Is cancer a special case of evolution?
Despite major overlaps between evolutionary biology and cancer biology, there are a few aspects of cancer evolution that indicate tumours may be a special case of evolutionary systems. First, tumours are extremely large populations, much larger than most common ecosystems and more akin to bacteria colonies, with populations in the order of hundreds of billions of cells. This implies that the total diversity is astounding. Another special feature of cancers is chromosomal instability, which is central to cancer evolution. Chromosomal instability allows for the generation of true hopeful monsters -grossly altered clones that may be adaptive -a phenomena thought to be very rare in species evolution. Cancer cell plasticity, or phenotypic change that does not require underlying heritable variation, is also a fundamental force that guides tumour adaptation and makes the system rather non-Darwinian in some contexts.
Subclones in a tumour, subclones refer to populations of cells that harbour the same set of genomic alterations.
Clonal evolution
A process by which genetic and epigenetic alterations create diversity that acts as a substrate for natural selection.
Genetic drift
A stochastic process that changes subclone frequency.
Selection
A non-random process shaped by environmental and tumour properties that changes subclone frequency.
Chromosome instability
(CiN). A type of genomic instability that involves parts of or entire chromosomes.
Phylogenetic tree
A branching diagram showing the hierarchy of clones within the tumour.
Mutator phenotypes
Phenotypes that result in increases in mutation rates in cancer.
Inferring evolutionary mode with genomics
Although adaptation occurs at the phenotypic level, measuring the tumour cell phenotype within its original environment is challenging. Surrogate measurements such as gene expression are informative, but given the complexity and plasticity of the cancer transcriptome and the contribution to gene expression signals from cells within the tumour microenvironment, they are often difficult to interpret in light of evolution. This is why, to date, genome profiling has been the preferred tool to study cancer evolution. However, there are several major caveats when we try to understand the phenotypes from studying the genotypes, a problem that has been tackled over decades in the field of molecular evolution. The key issue is that the cancer genotype-phenotype map, bar some notable exceptions, such as that for treatment resistance mutations, is largely un known. Therefore, mapping the tumour phylogenetic tree and the underlying adaptive traits remains difficult.
Bulk sequencing. The commonly used bulk sequencing, that is, profiling of a sample comprising many cells, imposes a major limitation on inferences about tumour evolution dynamics. Because the standard depth of sequencing is many orders of magnitude smaller (100-1,000×) than the number of cells in the sample (10 million to 1 billion), bulk sequencing only recovers mutations that are present in either all or the majority of cancer cells in a given sample. Each doubling of the cancer cell population halves the frequency of new mutations arising in the population; hence, after just seven doublings, new mutations are undetectable with 100× sequencing, and after ten doublings, new mutations are undetectable at a 1,000× sequencing depth. Thus, detecting selection that resulted in a limited clonal expansion (hundreds to thousands of cells) is problematic. Contamination by stromal cells imposes an additional challenge as it dilutes the frequency of cancer alleles. Thus, bulk sequencing mostly informs on the most recent common ancestor of the cells in the sample, a node in the phylogenetic tree that is extinct in the current malignancy. The more cells in the bulk sample, the older the most recent common ancestor is and, in the case of multi-region bulk sequencing, the shorter the apparent branches in the tree are. Mathematically, this phenomenon emerges from coalescent theory 16 . Consequently, different-sized samples can generate very different portraits of the clonal structure of a tumour.
Choice of sequencing assay. The relative abundance of passenger mutations, which are evolutionarily neutral and non-adaptive, over driver mutations, which are under positive selection, makes the passengers that hitchhike on a driver event very informative regarding clonal dynamics. Passenger mutations provide a genetic mark to distinguish different functional clones and, more specifically, the number of passenger mutations unique to a lineage is a measure of the molecular age of that clone. The variant allele frequency (VAF) determines clone abundance, and the proportion of passenger mutations shared between clones reveals their ancestry 8, 35 . The choice of sequencing assay (high-depth targeted panel, moderate-depth exome or lower-depth whole-genome sequencing) represents a trade-off between the need for high-depth sequencing to accurately recover clone frequency (or even detect the clone at all) versus genome-wide detection of passenger mutations that uniquely identify distinct clones. Moreover, because deeper sequencing provides a broader temporal window on cancer evolution, the choice of sequencing assay is a compromise between genome sequencing, which provides detail on the clonal architecture in only a short and early time window, versus deep targeted sequencing, which provides limited clonal information but greater temporal range. Here, deeper and broader (for example, more of the genome covered) sequencing is always preferred.
Allelic copy number correction. The study of evolutionary dynamics of cancer clones is fundamentally concerned with the relative frequencies of cancer clones over space and time. Many bioinformatics tools have been created to infer clonal frequencies from bulk sequencing data, such as PyClone 36 , SciClone 37 and PhyloWGS 38 . Broadly, these tools attempt to identify sets of mutations that are all at the same frequency and assign them to clones. These tools have been instrumental to the study of cancer evolution from bulk data. However, this task requires many prior inference steps, each of which risks the introduction of errors that are then propagated through the analysis. Structural alterations (loss, gain and rearrangements of genetic material) are common in cancer genomes and confound the interpretation of mutation frequency. Because structural alterations typically alter the copy number of a locus, they also have an impact on the relative frequency of any SNV mutation at that locus. Thus, to assign SNVs to clones, it is
Hopeful monster
An individual cell with a grossly altered genome compared with its ancestor, which may be adaptive. A hopeful monster is the result of punctuated change in the genome.
Punctuated equilibrium
Refers to rapid speciation events with long periods of intervening stasis.
Passenger mutations
Mutations that have no effect on clone fitness.
Variant allele frequency
(VAF).The relative frequency of a variant in a tumour sample, expressed as a percentage.
Size of clone

Time
Strong driver leads to selective sweep After a mutation is fixed, driver diversity is removed, and evolution then appears 'linear'
Evolution is always branched Between selective sweeps, evolution is neutral Fig. 1 | Modes of cancer evolution. Cancers evolve according to Darwinian rules: mutation and selection of beneficial new mutations drive the expansion of subclones, and between and within selected clones, the cellular populations experience neutral evolution. Different modes of evolution appear, depending on when and how the evolutionary process is sampled.
www.nature.com/nrg necessary to correct for the impact of a CNA to turn the allelic frequency of an SNV into a clone frequency. In theory, this is straightforward: the cellular abundance of any individual mutation is simply a product of its frequency and copy number. However, if the allelic copy number is incorrectly inferred, then the SNVs in that CNA will be scaled to the wrong frequency and hence could erroneously appear as a new clone. In a tumour sample composed of 50% cancer cells, the difference in frequency of an SNV present on one of three copies versus one of four copies is only ~3%, which is a level of accuracy that is rarely achievable with moderate-depth sequencing (~100×). Moreover, errors can stem from the initial inference of the copy number of the locus. Consequently, errors in the allelic copy number inference (how many copies of the genome are present at a given position) and SNV assignment to copy number states (how many allelic copies have the mutation) propagate to produce an erroneous clone phylogenetic tree and give a misleading picture of the clonal structure of a tumour. Considering only SNVs located in diploid regions and exploiting the hitchhiking principle 39 helps but, in a highly aneuploid genome, risks discarding the majority of SNVs for downstream evolutionary analysis, thus losing the signal for subclonal reconstruction.
It is important to note that clone identification is done according to the (abundant) hitchhiking mutations that define the clone, not from the drivers themselves. There remains a need for higher-resolution data (>100× depth at whole-genome resolution) and improved clonal decomposition methods that enable effective handling of error propagation and quantification of uncertainty. Emerging long-read and linked-read sequencing technologies also offer the hope of circumventing this issue, as long reads intrinsically phase mutations and thus directly reveal their allelic identity 40 .
Single-cell sequencing. Single-cell sequencing is an exciting, emerging alternative to bulk sequencing to explore tumour evolution [41] [42] [43] [44] [45] [46] [47] [48] . In theory, sequencing individual cells removes the time bias inherent to bulk sequencing, as all genetic mutations within the sequenced cell should be detectable irrespective of when the mutations arose. Clonal identity also becomes evident, removing the need for allelic copy number correction. However, calling SNVs in single-cell sequencing remains challenging owing to the level of noise and missing data. Combining information from multiple cells addresses this issue 49 , although at the cost of losing single-cell resolution. By contrast, CNAs can be reliably identified in single cells 50 ; however, because the background CNA rate is still not well understood 51 , drawing inferences about temporal evolutionary dynamics from these data is not straightforward. Nevertheless, single-cell sequencing offers a powerful route to learning how CNAs accrue, because sequencing individual cells means that some newly born cells can be analysed before the effects of selection, informing the background CNA mutation rate 51 . Single-cell sequencing of cells from a large cancer risks sequencing many cells that are 'evolutionary dead ends' and would not contribute to future disease progression. Simply sequencing large numbers of cells would abrogate this issue and moreover gives a direct means to detect and characterize negative selection on CNAs 52 , which cannot be identified by bulk sequencing. We expect single-cell sequencing to become the tool of choice in the future as sequencing costs continue to fall.
Detecting selection
Clonal selection drives cancer evolution; therefore, naturally, there is much interest in identifying the cause of a clone's selective advantage. However, detecting selection comes with several challenges (Fig. 2 ). There are two broad approaches for detecting selection: clone frequency-based methods and mutational pattern-based methods. The two approaches are complementary and should be used in conjunction.
Using clone frequency to detect selection. Broadly, frequency-based methods detect selection by looking for lineages that are more abundant than would be expected under neutral evolution. This is done by exploiting the VAF distribution, also often referred to as the site frequency spectrum, as a surrogate for lineage frequency in a sample. The appeal of this approach is that the shape of the VAF distribution under neutral evolution in a well-mixed population is well known: specifically, under neutral evolution, the number of mutations, m(f), as a function of allelic frequency f, follows a 1/f 2 distribution 6,7,53-55 . Multiregion sampling can also be used to measure clone frequency; selection for an ancestral clone causes it to have a disproportionate number of offspring in the phylogenetic tree constructed from these data 56 . Hybrid methods that simultaneously consider the VAF distributions from multiregion sampling also exist 57 .
Longitudinal sampling of clone abundance provides a particularly powerful method to detect selection; clones that grow disproportionately relative to others are likely under selection 58 . However, longitudinal tissue collection and temporal analyses of solid tumours are rendered challenging owing to the accessibility of tumour tissue. In due course, as sequencing technologies improve and costs decline, we anticipate that analyses of circulating cell-free tumour DNA will help to circumvent some of these challenges 59, 60 .
Frequency-based methods are limited by the power to detect small deviations from the null neutral model (for example, deviations from the 1/f 2 distribution) 8 . Weak selection (for example, a relative selective advantage of ~1%) causes only slow and slight shifts in clone frequency that may go undetected in moderate-depth sequencing 8 . Such weakly selected clones may never become detectable, especially if they arise too late 8, 61 , and may take longer than a human lifetime to become dominant. The spatial architecture of a tumour presents a complication too -selection is invisible if all samples are taken within the selected clone (Fig. 2) . Moreover, frequency-based methods can detect only ongoing differential selection within a population. Once a selected clone has taken over, reaching fixation, the new (fitter) population of tumour cells is homogeneous with respect to the selective alteration, and, hence, the within-tumour evolution reverts to neutral. In this case, dense longitudinal sampling is necessary to accurately detect selection. Thus, there are multiple caveats to inferring selection from single low-sequencing depth samples.
Using mutational patterns to detect selection.
Alternative methods use the burden and type of mutation across the genome to detect selection; we refer to these collectively as 'mutational pattern' methods. These methods exploit the fact that selection causes an Step 4) Selection occurs within a small niche that is below the detection limit such that evolution appears neutral because selected subclones are undetectable. (Step 5) Using frequency and/or phylogenetic methods, selection can only be detected when multiple subclones are sampled. b | Bulk sequencing data have profound time biases, permitting only the earliest -and so highest frequency -mutations to be detected. As a tumour doubles its cell number, new mutations that arise represent an exponentially smaller fraction of the tumour and thus rapidly fall below detectable frequency. c | Error in copy number and single-nucleotide variant mutation multiplicity assignment propagates and confounds the identification of tumour subclones. Limited depth sequencing (for example, 100×) causes dispersion in the true variant allele frequency (VAF), and true VAF is determined by clonal abundance and underlying copy number state (coloured shapes on plot). This leads to mutations in different clones or at different copy number states, being erroneously misassigned clonal identities. The 1/f 2 tail of low frequency mutations is an inevitable consequence of tumour growth and further complicates clonal inference on VAF data. CCF, cancel cell fraction. www.nature.com/nrg over-representation of mutations that increase fitness rather than neutral mutations, which measure lineage divergence 62 . Indeed, statistical tools to identify cancer driver mutations across tumours work by considering the frequency at which a gene is found to be mutated across cancers compared with the background expectation 63 . The dN/dS ratio -the ratio of nonsynonymous mutations (N mutations) to synonymous mutations (S mutations) normalized by their respective likelihood of occurrence -is a popular sequence-based method for detecting selection. The logic of the method is that nonsynonymous mutations will tend to experience selection, whereas synonymous mutations will be evolutionarily neutral, and hence positive selection will cause an overrepresentation of NS mutations (dN/dS > 1), whereas negative selection will cause an under-representation of NS mutations (dN/dS < 1) 64 . Driver genes should have positive dN/dS values 24 , and newly refined, powerful methods for dN/dS calculation have been developed specifically for use with cancer data 12, 14 .
For the dN/dS method to work, a sufficient number of mutations has to be under selection in the gene or locus to cause a statistically significant deviation of the ratio away from 1. Hence, a minimum mutation burden is required to calculate the ratio, and the method is challenging to apply to individual genes that have too few mutations in a cohort. Importantly, dN/dS methods provide average estimates of selection across a cohort of patients and are hard to apply to individual tumour evolutionary dynamics. Few patients with extensive positive selection could drive the dN/dS value of an entire cohort 65, 66 . Population demographics also influence the dN/dS ratio in a complex manner and potentially confound its interpretation 67, 68 . Nevertheless, combining frequency-based methods with mutational patternbased methods can partially overcome the limitations of each approach, providing more robust estimates of clonal selection.
Stochasticity versus determinism.
In small populations, both in cancer and in species, stochasticity can dominate the evolution of even strongly selected mutations 3 , but a large clone in a large population can behave more deterministically 69 . The clone size at which stochastic evolution becomes deterministic evolution is inversely proportional to the selective advantage of the mutant 22, 23, 58 . This evolutionary rule about the transition from stochasticity to determinism has implications for the predictability of cancer evolution: small, stochastically evolving clones have unpredictable evolution, whereas large clones evolve more predictably. In other words, we are likely to be able to accurately predict the evolution of clones that have already grown large enough to be detected; however, making an accurate prediction about the emergence of specific minor clones will be more challenging 70 .
Chromosome instability in cancer evolution CIN and clonal fitness. Alterations in copy number affect a greater proportion of the cancer genome than any other mutation 71 and can act as hopeful monsters 72 , offering potentially high adaptive advantage to evolving cancers. They result from CIN, a consequence of ongoing errors in chromosome segregation during mitosis and errors of DNA replication and repair 73, 74 . The end result is aneuploidy (an unbalanced chromosome complement) involving entire chromosomes (wholechromosome aneuploidy) or parts of chromosomes (partial or segmental aneuploidy). Aneuploidy can also occur independently of CIN if a single event of chromosome missegregation leads to expansion of the aneuploid clone. Such tumours are homogeneously or clonally aneuploid, whereas tumours with ongoing CIN are heterogeneously or subclonally aneuploid 75, 76 . In addition, aneuploidy can result from single catastrophic events, termed chromoplexy (if affecting multiple chromosomes) or chromothripsis (affecting 1-2 chromosomes), the relevance of which has become increasingly evident across different cancer types 77 . Irrespective of the mechanism, aneuploidy can alter the somatic copy number, and therefore the expression, of many genes at the same time. Although the background alteration rate varies substantially across chromosomes 51 , it does not account for evidence of recurrent chromosomal-level or arm-level aberrations in tumours 78 , which are likely explained by selection (both positive for CNA drivers or negative for lethal chromosomal states). The locations of tumour-suppressor genes and oncogenes recapitulate the patterns of aneuploidy observed across different cancers 79, 80 and also show the adaptive potential provided by CIN. In a mouse model of acute lymphoblastic leukaemia and hepatocellular carcinoma, induction of CIN in T cells and hepatocytes resulted in tumour-specific patterns of chromosome copy alterations 81 , suggesting that selective pressure is tissue context-dependent. CIN can also provide means of disease escape following curative treatment with surgery or disease control with targeted therapy. Induction of CIN in the KRAS model of lung cancer resulted in rapid relapse, with recurrent tumours showing high levels of aneuploidy and with emergent independence from the original oncogenic stimulus 82 . In chronic myeloid leukaemia, patients who developed resistance to the BCR-ABL-targeting imatinib developed additional chromosomal alterations 83 .
Some effects of CIN are independent of gene-specific alterations, including reduced proliferation, proteotoxic stress, metabolic changes, upregulation of the stress response and further genome instability. Additional genome instability in particular has a profound impact, as aneuploid cells continue to create more genetic diversity 84, 85 . The fact that aneuploidy (or CIN) can be both detrimental and advantageous highlights the importance of determining the selective landscape. This is well illustrated in yeast in which aneuploidy provides a fitness advantage under severe environmental conditions, acting as the "first evolutionary line of defense" 86 , but does not persist upon reversion to normal conditions. In a systematic study of the oncogenic potential of aneuploidy in mouse embryonic fibroblasts, trisomy failed to induce transformation under any conditions, and the cells grew poorly compared with matched euploid cells, consistent with a fitness penalty 87 . However, during longterm growth, triploid cells acquired other aneuploidies that conferred improved fitness. The authors suggest that low levels of aneuploidy may be tumour protective but Chromoplexy A complex rearrangement of the cancer genome that involves a number of chromosomes.
Chromothripsis
A complex rearrangement of the cancer genome that involves a single chromosome.
NATUre reviews | GenetICs that the genome-destabilizing effects of aneuploidy are tumour-promoting under certain growth conditions. Thus, the rare growth-promoting aneuploidies expand and rise to clonal levels, while growth-inhibitory aneuploidies are selected against. Consistent with this notion, aneuploid cells grew better than euploid cells under conditions of environmental stress such as hypoxia and chemotherapy 88 . Addition of a single chromosome increased the tolerance to environmental stresses and was not chromosome-specific, suggesting that overexpression of particular genes is not the only contributor to adaptive potential.
CIN and metastasis.
Complex processes of metastatic spread, which require a multitude of cellular phenotypes, could be well served by the karyotypic and phenotypic heterogeneity generated by CIN. Comparative studies of matched primary tumour-metastasis pairs have reported enrichment for aneuploidy in metastatic lesions from prostate, pancreatic, breast and colon cancers (reviewed elsewhere 89 ). Using a detailed clonal resolution of matched clear cell renal cell cancer (ccRCC) primary and metastatic tumours, we recently reported that a critical difference between tumour clones that are metastasis-competent compared with those that fail to metastasize is the degree of aneuploidy and chromosome complexity (measured by fluorescence-activated cell sorting and weighted genome instability index 90, 91 ). Furthermore, we observed that specific somatic CNAs, loss of 9p and loss of 14q were highly enriched within the metastasizing clones, reflecting active selection. We found no evidence of selection for the smaller-scale mutations such as SNVs 91 . Beyond altering the expression of many genes simultaneously, potential mechanisms by which chromosomal alterations contribute to metastasis include the induction of mesenchymal transition through changes in expression of intercellular junction proteins 92 , the activation of the cGASstimulator of interferon genes (STING) pathway by cytosolic DNA from chromosome missegregation [93] [94] [95] and immune evasion 96 .
CIN and clinical outcomes. The role of CIN in cancer evolution and progression is evidenced by its association with poor clinical outcomes in a number of retrospective studies 97, 98 . More recently, analyses in a prospective cohort of early-stage non-small-cell lung cancer (NSCLC) evolution (TRACERx Lung study) showed that CIN confers an increased risk of recurrence and death independently of known predictive markers 27 . In TRACERx Renal, a similarly prospective study of ccRCC, an increase in aneuploidy was associated with shorter progression-free and overall survival 26 . Intriguingly, the level of CIN has a bearing on its overall impact on prognosis. In a pan-cancer analysis of >2,000 samples, only moderate levels of CIN (>25% and <75%) were associated with decreased survival, concordant with previous studies showing that excessive levels of CIN confer an improved prognosis [99] [100] [101] . These observations are consistent with a fitness cost of CIN, with the selective advantage of karyotypic heterogeneity negated by excessive levels of aneuploidy.
CIN is also linked to resistance to anticancer treatment, including chemotherapy 102, 103 , and the CTLA4 and PD1 immune checkpoint inhibitors (CPIs) 96, 104 . In NSCLC, CIN can lead to subclonal loss of heterozygosity (LOH) in the genes encoding the human leukocyte antigen (HLA) 105 , with pervasive evidence of positive selection found for this event in tumours. In this context, HLA LOH facilitates accumulation of subclonal neo-antigens and further clonal evolution 105 . In ccRCC, we observed increased rates of HLA LOH in primary tumour subclones that were selected in metastatic sites 91 , highlighting again the role of immune evasion in metastasis.
Evolutionary patterns and patient outcomes
Whether understanding a tumour's evolutionary trajectory and evolutionary potential can help to predict patient outcomes remains a critical issue in the context of precision medicine.
Clonal diversity and clinical outcomes.
The presence of clonal diversity (both neutral and non-neutral) is expected to provide a rich repertoire of alterations that could be adaptive under the selective pressure of therapy, alterations in the tumour environment or metastatic colonization of distant sites. In a prospective study of Barrett oesophagus, a premalignant condition, progression to adenocarcinoma correlated with clonal diversity independently of other genetic risk factors 106 . Multiple studies have demonstrated the link between subclonal diversification and adverse clinical outcomes in chronic lymphocytic leukaemia 107, 108 , head and neck cancer 109 , ovarian cancer 110 and across other cancer types 111 . Subclonal diversification of somatic CNAs and mutational drivers was associated with adverse prognostic features in ccRCC and independently associated with reduced progression-free and overall survival 26 . In NSCLC, diversity of somatic CNAs but not SNVs correlated with the risk of relapse and death 27 . In patients with breast cancer, intratumour heterogeneity of HER2 (also known as ERBB2) copy number, detected at singlecell resolution, was associated with shorter survival 112 . In multiple myeloma, detection of neutral evolution dynamics correlated with progression-free and overall survival 113 and was associated with the presence of a strong clonal (truncal) oncogenic driver, which might explain the lack of ongoing selection.
Punctuated versus gradual evolution and clinical pheno types.
It is increasingly apparent that some tumours acquire multiple and/or strong drivers in a short period of time (punctuated evolution), whereas others show a steadier rate of driver acquisition (gradual evolution) 10, [114] [115] [116] . The result of punctuated evolution is a rapid clonal sweep and a functionally homogeneous tumour mass. In ccRCC, these tumours are characterized by low driver intratumour heterogeneity and high levels of clonal aneuploidy that became fixed early in tumour evolution 26 . Such tumours proliferated faster, disseminated rapidly to many different sites (Fig. 3a) and had worse outcomes than those characterized by clonal diversity and subclonal aneuploidy. Metastases from www.nature.com/nrg rapidly evolving tumours were seeded by the same dominant clone found at the primary site, resulting in limited intermetastatic heterogeneity in untreated patients (Fig. 3a) . By contrast, tumours with subclonal aneuploidy, evolving in a Darwinian fashion and gradually accumulating driver alterations, grew more slowly and over longer periods of time 26 . In some cases, meta stases were seeded by multiple clones, resulting in intermetastatic heterogeneity (in untreated patients). In line with this finding, a mathematical model of metastases formation suggests that the probability of observing intermetastatic heterogeneity (which results from distinct clones in the primary tumour seeding different metastatic sites) increases when the primary tumour grows slowly 117 . Intriguingly, gradually evolving tumours were also associated with a specific pattern of metastatic progression, termed oligometastases 91 (Fig. 3b ). Oligometastases, defined as a small number of lesions confined to a single site, are conceptualized as an intermediate state of metastatic capacity 118, 119 with an important clinical implication for directed, potentially curative treatment for such lesions. Reduced metastatic efficiency of clonally diverse tumours could be a result of clonal interference (interclonal competition at the primary tumour site) or a reflection of weak clonal drivers, with subclonal driver events providing the additional fitness required for metastases.
Pancreatic cancer has traditionally been viewed as following gradual evolution, with sequential acquisition of driver events. However, some pancreatic cancers show punctuated equilibrium as the principal evolutionary trajectory, whereby multiple driver events are acquired sometimes through a single catastrophic event, resulting in complex genomic rearrangements 120 . Consistent with our observations in renal cancer, such evolutionary trajectories result in limited intermetastatic heterogeneity, as all metastases are seeded by the dominant primary tumour clone 121 . Another example is uveal melanoma, which is characterized by aggressive, albeit latent, liver metastases in a proportion of patients, especially those whose primary tumour harbours BAP1 mutations. BAP1 mutations and chromosomal complexity were shown Fig. 3 | Clonal evolution and metastases. Different modes of evolution in the primary tumour can impact the mode of metastatic progression 26 . Metastatic capacity is associated with increased chromosome complexity 91 . a | Tumours that evolve in a punctuated fashion with early onset of clonal chromosome complexity grow rapidly and metastasize early and widely. Metastases are monophyletic (a single dominant clone seeds all the metastatic sites) and monoclonal (a single clone seeds a single site), and there is limited intermetastatic heterogeneity. b | Tumours that evolve in a branched (Darwinian) fashion grow more slowly and are composed of distinct subpopulations of cells with differential metastatic capacity. Chromosome complexity is acquired late, and they are associated with solitary or oligometastases. When they spread to multiple sites, they may do so in a polyphyletic fashion (different subclones seed different sites), which may include organ-specific patterns and result in intermetastatic heterogeneity 117 . If multiple clones seed the same site, the metastasis is polyclonal.
to arise in a short burst early on in tumorigenesis 114 , implying that metastatic potential can be acquired at the earliest stages of cancer evolution. Similar observations have been made in triple-negative breast cancer 116 , while chromoplexy and chromothripsis were shown to fuel rapid evolution in prostate cancer and colorectal cancer 115, 122 , respectively. Finally, the temporal order in which mutations are acquired during tumour evolution affects the clinical phenotype and outcome of myeloproliferative neoplasms 123 , ccRCC 26 , NSCLC and breast cancer 124 , pointing to the evidence of evolutionary constraints.
The observation of a wide spectrum of evolutionary patterns in cancer begins to reconcile the diverse clinical phenotypes and varied outcomes seen in the clinic. In particular, the occurrence of punctuated genomic evolution highlights the challenge of managing cancers that acquire metastatic competency early, the cancers that are 'born to be bad' . Supporting this notion are preclinical models that show metastatic dissemination before frank malignancy is detected histologically 125 . These observations are especially relevant for cancer screening approaches. As the latency between the emergence of the invasive clone and metastatic spread can be short, the window for early detection could be very limited 126 . Many questions about evolutionary trajectories remain, including the environmental conditions that favour gradual evolution (gradual accumulation of driver mutations) or punctuated evolution (large-scale rearrangements of the genome leading to many drivers acquired at once) and how these may be altered for therapeutic benefit.
Origin of treatment-resistant clones
Despite continuing advances in the treatment of cancer, metastatic tumours remain largely incurable. Understanding how treatment resistance evolves under the selective pressure of therapy can inform novel strategies to delay or prevent its onset.
Resistance to targeted therapies. Targeting oncogenic drivers in both blood and solid malignancies has brought about a remarkable change in the cancer treatment landscape. Notable examples include BCR-ABL translocation in chronic myeloid leukaemia, for which the use of imatinib has resulted in 10-year survival of ~85% 127 ; KIT mutations in gastrointestinal stromal tumours; HER2 amplification in breast cancer; EGFR mutations in NSCLC; and BRAF mutations in melanoma. However, with the exception of chronic myeloid leukaemia, disease control afforded by targeted agents is fairly short-lived, and treatment rarely results in longterm survival for the patient. Mutational complexity of solid cancers may be a contributing factor to the inevitability of resistance, as every additional mutation could provide a pathway to treatment resistance. Accordingly, higher tumour mutational burden correlates with shortened benefit from EGFR tyrosine kinase inhibitor treatment in metastatic EGFR-mutant NSCLC 128 . While resistance mutations can arise de novo 129 , they frequently pre-exist as minor subclones 130, 131 (Fig. 4) . However, the ability to detect them in pretreatment samples is limited by the breadth of sampling as well as the depth of sequencing. Modelling of tumour growth suggests that detectable metastatic lesions can harbour ten or more resistant subclones 132 , and although there are limitations to these models (reviewed elsewhere 133 ), the predictions are consistent with the observations in clinical and genomic data. In a recent study of patients with chronic lymphoid leukaemia treated with ibrutinib, resistance was attributable to the emergence of mutations in BTK and/or PLCG2, which were detected with a high-sensitivity method up to 15 months before clinical progression, with some patients evolving multiple resistance mutations 134 . Polyclonal treatment resistance has been described in other tumour types, with evidence of parallel expansion of clones harbouring distinct mechanisms of resistance under selective pressure of therapy [135] [136] [137] . Upfront evaluation of the resistant clones can also be used to forecast the duration of therapeutic benefit, as recently demonstrated in metastatic colorectal cancer using frequent time-course liquid biopsy and mathematical modelling 138 .
Thus, a comprehensive catalogue of resistant mutations could inform appropriate combinatorial strategies, while dynamic monitoring of emerging and resolving alterations can facilitate adaptive treatment strategies. This approach was well illustrated by the example of EGFR inhibition in colorectal cancer and the waxing and waning of the resistant RAS mutant alleles in blood in response to treatment initiation and withdrawal 139 . can be present in the tumour population before the start of therapy , usually as a minor subclone 132, 134 . They may evade detection in the baseline sample if they are present at very low frequency or are restricted to an unsampled region of the tumour. They may even be neutral or deleterious before therapy. Under the selective pressure of therapy , the treatment-sensitive population diminishes, leaving the resistant population to expand under positive selection. Multiple subclones bearing distinct resistant mutations can emerge at the same time, indicating parallel evolution of resistance [135] [136] [137] [138] . b | Treatment resistance can be a result of a de novo mutation that carries a selection advantage under therapy and becomes fixed in the tumour population. In this case, resistance takes longer to emerge 129 .
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These observations also highlight the issue of fitness penalty associated with resistant mutations: KRAS mutations were detected in cell-free DNA from patients who developed resistance to EGFR inhibition; however, when therapy was withdrawn, they remained undetectable, suggesting that they require ongoing therapy for their maintenance and that resistance comes at a cost 139 . The higher the fitness cost, the harder it is for the resistant clone to emerge, as modelled in patient-derived xenografts from individuals with BRAF-V600E mutant melanoma or NSCLC, who developed resistance to BRAF inhibition. Patient-derived xenografts were exposed to ERK (also known as MAPK) inhibition (downstream of BRAF), which resulted in multiple BRAF-amplified clones being selected and propagated. When BRAF, MEK (also known as MAPKK) and ERK inhibitions were combined in an intermittent schedule, the fitness disadvantage prevented the emergence of the BRAF-amplified subclones 140 . Finally, clonal complexity may affect the drug target itself. Although frequently clonal by virtue of being founder alterations, drug targets can also be present in tumour subclones. In a recent clinical trial, FGFR inhibitor responders harboured a clonal FGFR amplification, whereas nonresponders harboured subclonal amplifications 141 .
Resistance to immune checkpoint inhibition.
Another important development in cancer therapeutics has been the advent of immune checkpoint blockade. The efficacy of CPIs is contingent on pre-existing recognition of the tumour by the immune system through presentation of neo-antigens that result from somatic mutations accumulated by the tumour 142 . Accordingly, CPIs have been most effective in tumour types with an abundance of somatic mutations (that is, a high tumour mutational burden) 143 , which increases the likelihood of a potent neo-antigen being presented to the immune system. Initially, it was expected that CPIs might circumvent the clonal diversity faced by targeted therapies; however, it has become apparent that clonal evolution has a profound impact on immunotherapy success and failure. For example, subclonal neo-antigens do not stimulate an adequate tumour response, as shown by reduced sensitivity to checkpoint blockade in melanoma and NSCLC tumours that have a significant burden of subclonal mutations 144 . This pattern was confirmed across additional tumour types 145 . Neo-antigen evolution, or immune editing, underlies some aspects of acquired resistance to CPIs. Loss of both clonal and subclonal neo-antigens under selective pressure of CPI treatment has been reported. Clonal neo-antigens are lost through deletion of the chromosome region that harbours the alteration, whereas subclonal neo-antigens are lost through outgrowth of alternative subclones 146 . Critically, peptides generated from the lost neo-antigens elicit clonal T cell expansion in autologous T cell cultures 146 , suggesting they generated functional immune responses. Neo-antigen immune editing has also been reported in the context of adoptive transfer of autologous lymphocytes that specifically target proteins encoded by cancer-specific mutations, another area of active clinical development that holds much promise 147 .
T cell-recognized neo-antigens were selectively lost over time in metastatic melanomas treated by adoptive T cell transfer, accompanied by the development of neoantigen-specific T cell reactivity in tumour-infiltrating lymphocytes 148 , which indicatesimmune editing.
Inactivation of antigen presentation is another important mechanism of acquired CPI resistance. Examples include point mutations, deletions or LOH in B2M (which encodes an essential component of major histocompatibility complex class I antigen presentation), and in the genes encoding interferon receptorassociated Janus kinase 1 (JAK1) or JAK2 (ReFs 43, 149 ). Just as with the drivers of resistance to targeted therapy, these alterations were selected and expanded under therapy. Vaccine strategies are also vulnerable to evolution of resistance. In a trial of an RNA-based vaccine against a spectrum of cancer mutations, neoepitope-specific killing was demonstrated in a patient who initially responded but developed resistance owing to the outgrowth of β 2 -microglobulin-deficient melanoma cells 150 . Another mechanism of immune evasion occurs through selection of tumour cell populations in which HLA is either mutated or lost. In a recent report of adoptive T cell transfer specifically targeting mutant KRAS in a patient with colorectal cancer, profiling of a progressive lesion revealed genetic loss of the HLA that was required for tumour recognition by the transferred reactive T cells 151 .
Conclusions and perspective
An understanding of the dynamics of cancer evolution might lead to improvement in clinical outcomes, as it would enable prognoses to be accurately determined and 'evolution-aware' patient management to be applied. Genomic analysis provides a quantitative measurement of evolutionary dynamics and evolutionary potential. There is tremendous value still to be gleaned from analyses of the rapidly growing public repository of cancer genomic data; particular insight can be gained from the large sample numbers and the intercomparison of evolutionary dynamics between cancer types. However, we caution that our inferences are severely restricted by the limitations of single-biopsy-based, bulk-sequenced data sets. As sequencing costs continue to fall, deeper sequencing (for example, exceeding the current best of 100× the entire genome) will allow more accurate determination of clonal fractions (reducing error on inferences derived from these data) and enable the resolution of smaller clones. Single-cell sequencing technology promises to circumvent much of the complexity of bulk sequencing data, and this maturing technology promises a concurrent measurement of genotypes and phenotypes in individual cells 152 together with a characterization of their in situ microenvironment 42 .
Improving the availability of samples from which to study cancer evolutionary dynamics also presents a bottleneck; we hope initiatives such as our TRACERx 153 and PEACE 154 studies, which provide infrastructure for longitudinal and post-mortem collection of tumour samples, will become more common. Even at a single time point, these studies provide greater representative tumour sampling than single-tumour biopsy samples do,
Patient-derived xenografts
Tumour models in which the tissue from a patient's tumour is implanted in an immunodeficient mouse.
Immune checkpoint blockade
Refers to therapies that target immune checkpoints such as CTLA4 and PD1 that tumours can use to escape antitumour immune responses. which under-represent tumour bulk, leading to the risk of illusion of clonality. Quantitative genomic analysis of liquid biopsy samples (the analysis of tumour DNA from peripheral blood samples) may overcome this issue and provide an amenable route for minimally invasive longitudinal disease monitoring as well as predictions on disease course and treatment response 59, 138, [155] [156] [157] . In summary, evolutionary genomics provides an everimproving lens to reveal the clonal dynamics of cancer and to impact patient outcomes.
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